These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37596639)

  • 1. ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors.
    Shin SH; Ju EJ; Park J; Ko EJ; Kwon MR; Lee HW; Son GW; Park YY; Kim YJ; Song SY; Lee S; Seo BS; Song JA; Lim S; Jung D; Kim S; Lee H; Park SS; Jeong SY; Choi EK
    Cancer Cell Int; 2023 Aug; 23(1):172. PubMed ID: 37596639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
    Feng Y; Lee J; Yang L; Hilton MB; Morris K; Seaman S; Edupuganti VVSR; Hsu KS; Dower C; Yu G; So D; Bajgain P; Zhu Z; Dimitrov DS; Patel NL; Robinson CM; Difilippantonio S; Dyba M; Corbel A; Basuli F; Swenson RE; Kalen JD; Suthe SR; Hussain M; Italia JS; Souders CA; Gao L; Schnermann MJ; St Croix B
    Cell Rep; 2023 Dec; 42(12):113503. PubMed ID: 38019654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
    Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
    Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.
    Kendsersky NM; Lindsay J; Kolb EA; Smith MA; Teicher BA; Erickson SW; Earley EJ; Mosse YP; Martinez D; Pogoriler J; Krytska K; Patel K; Groff D; Tsang M; Ghilu S; Wang Y; Seaman S; Feng Y; Croix BS; Gorlick R; Kurmasheva R; Houghton PJ; Maris JM
    Clin Cancer Res; 2021 May; 27(10):2938-2946. PubMed ID: 33619171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
    Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
    Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
    Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
    Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
    Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma.
    Mao Y; Wei D; Fu F; Wang H; Sun Z; Huang Z; Wang Y; Zhang G; Zhang X; Jiang B; Chen H
    Eur J Med Chem; 2023 Sep; 257():115489. PubMed ID: 37235999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
    Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
    Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.
    Koumprentziotis IA; Theocharopoulos C; Foteinou D; Angeli E; Anastasopoulou A; Gogas H; Ziogas DC
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
    Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
    Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity.
    Feng Y; Xie K; Yin Y; Li B; Pi C; Xu X; Huang T; Zhang J; Wang B; Gu H; Fang J
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
    Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
    Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC.
    Wu H; Liu C; Yuan Q; Qiao Y; Ding Y; Duan L; Li W; Zhang M; Zhang X; Jiang Y; Lu J; Dong Z; Wang T; Liu K; Zhao J
    Oncoimmunology; 2023; 12(1):2282250. PubMed ID: 38126034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors.
    Rosenkrans ZT; Erbe AK; Clemons NB; Feils AS; Medina-Guevara Y; Jeffery JJ; Barnhart TE; Engle JW; Sondel PM; Hernandez R
    bioRxiv; 2024 May; ():. PubMed ID: 38853889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3/CD276 and small-cell lung cancer: What's new?
    Fabrizio FP; Muscarella LA; Rossi A
    Transl Oncol; 2024 Jan; 39():101801. PubMed ID: 37865049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
    Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
    Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.